Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma

PURPOSE: A randomized, phase III trial demonstrated superiority of sunitinib over interferon alfa (IFN-α) in progression-free survival (primary end point) as first-line treatment for metastatic renal cell carcinoma (RCC). Final survival analyses and updated results are reported. PATIENTS AND METHODS...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Motzer, Robert J., Hutson, Thomas E., Tomczak, Piotr, Michaelson, M. Dror, Bukowski, Ronald M., Oudard, Stéphane, Negrier, Sylvie, Szczylik, Cezary, Pili, Roberto, Bjarnason, Georg A., Garcia-del-Muro, Xavier, Sosman, Jeffrey A., Solska, Ewa, Wilding, George, Thompson, John A., Kim, Sindy T., Chen, Isan, Huang, Xin, Figlin, Robert A.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Clinical Oncology 2009
Témata:
Original Reports
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3646307/
https://ncbi.nlm.nih.gov/pubmed/19487381
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2008.20.1293
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky